COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,358 Articles (22,803 medRxiv, 8,555 bioRxiv)

Most recent first Previous |  Page 1056: Articles 10551-10560  | Next

A systematic review of observational methods used to quantify personal protective behaviours among members of the public during the COVID-19 pandemic, and the concordance between observational and self-report measures in infectious disease health protection
Davies, R., Mowbray, F., Martin, A. F., Smith, L. E., Rubin, G. J.
10.1101/2021.12.22.21268226 — Posted: 2021-12-23
Persistent symptoms among children and adolescents with and without anti-SARS-CoV-2 antibodies: a population-based serological study in Geneva, Switzerland
Dumont, R., Nehme, M., Lorthe, E., De Mestral, C., Richard, V., Lamour, J., Baysson, H., Semaani, C., Pennacchio, F., Perrin, A., L'Huillier, A. H., Posfay Barbe, K., Pullen, N., Zaballa, M. E., Guessous, I., Stringhini, S.
10.1101/2021.12.23.21268298 — Posted: 2021-12-23
A magnetic bead immunoassay to detect human IgG reactive to SARS-CoV-2 Spike S1 RBD produced in Escherichia coli
Conzentino, M. d. S., Goncalves, A. C., Paula, N. M., Rego, F. G., Zanette, D., Aoki, M., Nardin, J. M., Huergo, L. F.
10.1101/2021.12.22.21268286 — Posted: 2021-12-23
Efficacy of antiviral drugs against the omicron variant of SARS-CoV-2.
Dabrowska, A., Szczepanski, A., Botwina, P., Mazur-Panasiuk, N., Jirincova, H., Rabalski, L., Zajic, T., Popowicz, G., Pyrc, K.
10.1101/2021.12.21.473268 — Posted: 2021-12-23
Nucleocapsid 203 mutations enhance SARS-CoV-2 immune evasion
Lin, X., Xue, W., Zhang, Y., Fu, B., Trimpert, J., Xing, N., Kunec, D., Tang, W., Xiao, Y., Meng, K., Shi, S., Wu, H., Meng, G., Zhu, Z.
10.1101/2021.12.20.473471 — Posted: 2021-12-23
Construction of a potent pan-vaccine based on the evolutionary tendency of SARS-CoV-2 spike protein.
Zhao, Y., Ni, W., Liang, S., Dong, L., Xiang, M., Cai, Z., Niu, D., Zhang, Q., Wang, D., Zheng, Y., Zhang, Z., Zhou, D., Guo, W., Pan, Y., Wu, X., Yang, Y., Jing, Z., Jiang, Y., SARS-CoV-2 Vaccine Task Force Group, , Chen, Y., Yan, H., Zhou, Y., Xu, K., Lan, K.
10.1101/2021.12.21.473594 — Posted: 2021-12-23
Anti-SARS-CoV-2 human antibodies retaining neutralizing activity against SARS-CoV-2 B.1.1.529 (omicron)
Imbrechts, M., Kerstens, W., Rasulova, M., Vercruysse, T., Maes, W., Ampofo, L., Ven, K., Lammertyn, J., Vanhoorelbeke, K., Callewaert, N., Neyts, J., Dallmeier, K., Declerck, P., Thibaut, H. J., Geukens, N.
10.1101/2021.12.21.473706 — Posted: 2021-12-23
Structural basis for antibody resistance to SARS-CoV-2 omicron variant
Cerutti, G., Guo, Y., Lihong, L., Zhang, Z., Liu, L., Luo, Y., Huang, Y., Wang, H. H., Ho, D. D., Sheng, Z., Shapiro, L.
10.1101/2021.12.21.473620 — Posted: 2021-12-23
Minimal observed impact of HLA genotype on hospitalization and severity of SARS-CoV-2 infection
Nguyen, A., Yusufali, T., Hollenbach, J., Nellore, A., Thompson, R. F.
10.1101/2021.12.22.21268062 — Posted: 2021-12-22
The Geometry of ATG-Walks of the Omicron SARS CoV-2 Virus RNAs
Kouzaev, G.
10.1101/2021.12.20.473613 — Posted: 2021-12-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).